Your search for ‘Brunet & Co’ returned 10 results

In our July 2025 analysis, "The Semaglutide Story: Highlighting the Need to Maintain Patent Protection in Canada," we examined the vulnerabilities exposed by the lapse...

The U.S. Special 301 Report is an annual review conducted by the Office of the United States Trade Representative (USTR) that evaluates the intellectual property (IP) protection and enforcement practices of U.S. trading partners.

Semaglutide, the blockbuster GLP-1 receptor agonist marketed under names like Ozempic® (type 2 diabetes) and Wegovy® (weight loss), has rapidly become one of the most consequential drugs in modern healthcare.

Intellectual property (IP) law is essential for protecting innovation, creativity, and brand identity, and for Canadian businesses expanding into the U.S. or operating across borders, a clear understanding of the differences and similarities between the two systems is critical.

In a major move that is making headlines across the Canadian retail industry, Hudson's Bay Company (HBC) has announced the sale of its brand name, trademark stripes, and associated intellectual property to Canadian Tire Corporation for $30 million CAD.

In today's global economy, businesses, entrepreneurs, and creatives frequently operate across borders.

Expanding into Asia offers Canadian businesses enormous potential—but it also exposes them to serious intellectual property (IP) risks.